Egret Therapeutics Enhances Commitment to Military Health with Dr. Geoffrey Ling's Appointment

Egret Therapeutics Appoints Dr. Geoffrey Ling to Scientific Advisory Board



Egret Therapeutics, a clinical stage biotechnology company focused on promoting tissue preservation following acute injuries, recently revealed the addition of Dr. Geoffrey Ling, MD, PhD, to its Scientific Advisory Board (SAB). Known for his expertise in neurology and military health research, Dr. Ling's appointment comes at a critical time as the company intensifies its mission to create therapies addressing urgent military medical needs, particularly traumatic brain injury (TBI) and spinal cord injury (SCI).

As a professor at Johns Hopkins University and the Uniformed Services University of the Health Sciences, Dr. Ling brings a wealth of knowledge to Egret. He previously served as the founding director of DARPA's Biological Technologies Office, where he spearheaded innovative programs directed at combat-related medical challenges, including the ongoing PREVENT program designed to address blast-induced brain injuries and the Revolutionizing Prostheses initiative focusing on brain-controlled prosthetics.

Dr. Ling’s multidisciplinary career encompasses an extensive background in neurocritical care provided in combat settings, impactful advisory roles in federal health innovation, and over 150 scientific publications that underscore his leadership in military medicine. His diverse experience will significantly enrich Egret's strategic focus on developing solutions that enhance the health outcomes of service members and civilians alike.

"The addition of Dr. Ling to Egret's team represents a significant milestone as we align our goals with the unique health challenges faced by military personnel," stated Dr. Daniel Chai, Co-Founder of Egret Therapeutics.


While Egret's primary research initiative currently concentrates on addressing acute ischemic strokes, its overarching objective is to mitigate secondary injuries following a range of acute insults—both traumatic and ischemic. This approach encompasses high-priority medical areas such as heart attacks, where safeguarding tissue structure and function is essential for long-term recovery.

Dr. Geoffrey Ling expressed his enthusiasm about his new role, emphasizing, "Egret Therapeutics stands at the forefront of transforming care for both military service members and the general populace suffering from serious injuries. Their innovative approach to preserving tissue following acute trauma poses opportunities to advance military medicine. It is an honor to join Egret’s SAB and contribute towards accelerating the development of much-needed therapies that address the urgent needs of our nation’s protectors."

In supporting Dr. Ling’s joining of the board, Vedik Navale, Chief of Staff at Egret Therapeutics, remarked, "Dr. Ling's elite expertise in neurotrauma and military health serves as a testament to Egret’s refined mission. His insights will propel our efforts in delivering groundbreaking therapies to individuals impacted by severe injuries."

About Egret Therapeutics



Egret Therapeutics is focused on advancing technologies that modulate innate immunity to preserve normal tissue structure and function following acute injuries. The company's comprehensive platform aims to counteract the stereotypical mechanisms that trigger secondary injuries across a variety of acute conditions, which often result in long-term disabilities. Egret is actively pursuing clinical indications within areas such as neurology, cardiovascular health, trauma, and spinal conditions.

In light of these developments, the future looks promising for Egret Therapeutics as they continue to pursue their vital mission to enhance military and civilian health outcomes through innovative medical therapies.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.